The role of cardiac biomarkers in cardiovascular disease risk assessment

Current Opinion in Cardiology

Volumn 29, Issue 4, 2014, Pages 366-371

  Collinson, Paul ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

B type natriuretic peptide; Cardiovascular biomarker; Cardiovascular risk assessment; Growth differentiation factor 15; High sensitivity cardiac troponin

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATION FACTOR 15; TROPONIN I; TROPONIN T; GDF15 PROTEIN, HUMAN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HUMAN; INFLAMMATION; MYOCARDITIS; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; CARDIOVASCULAR DISEASES; RISK ASSESSMENT; RISK FACTOR;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; NATRIURETIC PEPTIDE, BRAIN; RISK ASSESSMENT; RISK FACTORS; TROPONIN I; TROPONIN T;

EID: 84904794653     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000081     Document Type: Review

References (37)

1. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
2. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355:2615-2617.
3. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-935.
4. Mallett S, Halligan S, Thompson M, et al. Interpreting diagnostic accuracy studies for patient care. BMJ 2012;345:e3999.
5. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-2567.
6. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
7. Collinson PO, Clifford-Mobley O, Gaze D, et al. Assay imprecision and 99th-percentile reference value of a high-sensitivity cardiac troponin I assay. Clin Chem 2009;55:1433-1434.
8. Collinson PO, Heung YM, Gaze D, et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219-225.
9. Koerbin G, Abhayaratna WP, Potter JM, et al. Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. Clin Biochem 2013;46:1636-1643.
10. McKie PM, Heublein DM, Scott CG, et al. Defining high-sensitivity cardiac troponin concentrations in the community. Clin Chem 2013;59:1099-1107.
11. DeFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-2502.
12. De Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-2512.
13. Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011;123:1367-1376.
14. Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-1604. To date, the only published study that has systematically compared the putative readily available cardiac biomarkers for risk prediction in the primary care population. A range of outcomes have been studied, showing GDF-15 to be the best overall mortality predictor and BNP the best predictor of heart failure.
15. Zeller T, Tunstall-Pedoe H, Saarela O, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 2014;35:271-281. The most recent study that has examined the role of high-sensitivity troponin as a prognostic risk marker. Its findings are complementary to the other studies cited in the text.
16. Ndrepepa G, Braun S, Schulz S, et al. High-sensitivity troponin T level and angiographic severity of coronary artery disease. Am J Cardiol 2011;108:639-643.
17. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart 2011;97:823-831.
18. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-675.
19. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-1021.
20. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-663.
21. Kara K, Mahabadi AA, Berg MH, et al. Predicting risk of coronary events and all-cause mortality: role of B-type natriuretic peptide above traditional risk factors and coronary artery calcium scoring in the general population: the Heinz Nixdorf Recall Study. Eur J Prev Cardiol 2013. [Epub ahead of print]
22. Leistner DM, Klotsche J, Pieper L, et al. Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the populationbased DETECT study. Clin Res Cardiol 2013;102:259-268. A large-scale primary care study demonstrating the additive value of BNP measurement to conventional risk stratification models.
23. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-49.
24. Yanagawa B, Nagaya N. Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids 2007;32:157-164.
25. Von Haehling S, Papassotiriou J, Morgenthaler NG, et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int J Cardiol 2012;162:27-32.
26. Apple FS, Steffen LM, Pearce LA, et al. Increased cardiac troponin I as measured by a high-sensitivity assay is associated with high odds of cardiovascular death: the Minnesota Heart Survey. Clin Chem 2012;58:930-935.
27. Neumann JT, Tzikas S, Funke-Kaiser A, et al. Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease. Atherosclerosis 2013;228:451-459.
28. Eggers KM, Venge P, Lindahl B, Lind L. Associations of mid-regional proadrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community. Int J Cardiol 2013;168:3537-3542.
29. Chen LQ, de Lemos JA, Das SR, et al. Soluble ST2 is associated with allcause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clin Chem 2013;59:536-546.
30. Rohatgi A, Patel P, Das SR, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations fromthe Dallas Heart Study. Clin Chem 2012;58:172-182.
31. Eggers KM, Kempf T, Wallentin L, et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in communitydwelling elderly individuals. Clin Chem 2013;59:1091-1098. A large-scale study in the healthy elderly demonstrating that GDF-15 changes with time predict mortality.
32. Wallentin L, Zethelius B, Berglund L, et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One 2013;8:e78797.
33. Xanthakis V, Larson MG, Wollert KC, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. J Am Heart Assoc 2013;2:e000399.
34. Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-1549.
35. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-360.
36. Eggers KM, Kempf T, Lind L, et al. Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand J Clin Lab Invest 2012;72:45-51.
37. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-1256.